Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants

(2017) Maarten Timmers et al.   JOURNAL OF ALZHEIMERS DISEASE

BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology

(2017) Sandra D. Mulder et al.   JOURNAL OF ALZHEIMERS DISEASE

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology

(2016) Philip S. Insel et al.   NEUROLOGY

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

(2016) Riqiang Yan   Translational Neurodegeneration

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid

(2013) Soraia Barao et al.   Current Alzheimer Research

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Alzheimer's disease: strategies for disease modification

(2010) Martin Citron   NATURE REVIEWS DRUG DISCOVERY

Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease

(2008) Henrik Zetterberg et al.   ARCHIVES OF NEUROLOGY

Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

(2008) P Lewczuk et al.   MOLECULAR PSYCHIATRY